eisai royalty pharma | Royalty Pharma Announces Agreement to Purchase

Keyword	CPC	PCC	Volume	Score	Length of keyword
eisai royalty pharma	1.22	0.5	5614	64	20
eisai	1.02	0.5	6714	85	5
royalty	1.6	0.9	4938	8	7
pharma	0.9	0.8	5020	77	6

Keyword	CPC	PCC	Volume	Score
eisai royalty pharma	1.34	0.5	3707	91

Search Results related to eisai royalty pharma on Search Engine

Royalty Pharma Announces Agreement to Purchase Future …
royaltypharma.com

https://www.royaltypharma.com/news/royalty-pharma-announces-agreement-purchase-future-royalties/

WEBNov 5, 2019 · Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.’s royalties on future worldwide sales of tazemetostat, Epizyme Inc.’s (Nasdaq: EPZM) lead investigational agent, outside.

DA: 34 PA: 71 MOZ Rank: 1

Royalty Pharma Announces Agreement to Purchase Future …
prnewswire.com

https://www.prnewswire.com/news-releases/royalty-pharma-announces-agreement-to-purchase-future-royalties-on-tazemetostat-from-eisai-for-330-million-and-a-100-million-initial-investment-in-epizyme-300951746.html

WEBNov 5, 2019 · Under the terms of its agreement with Eisai, Royalty Pharma has acquired Eisai's future worldwide royalties on net sales by Epizyme of tazemetostat outside of Japan, for an upfront...

DA: 69 PA: 94 MOZ Rank: 54

EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES …
eisai.com

https://www.eisai.com/news/2019/news201981.html

WEBNov 5, 2019 · Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over $4 billion in royalties on pre-approval products and committed over $900 million to direct R&D funding in exchange for royalties. More information on Royalty Pharma is available at www.royaltypharma.com. Full text

DA: 62 PA: 93 MOZ Rank: 60

Eisai transfers royalty rights for tazemetostat to Royalty Pharma
pharmaceutical-technology.com

https://www.pharmaceutical-technology.com/news/eisai-tazemetostat-royalty-pharma/

WEBNov 6, 2019 · Under the terms of the latest agreement, Eisai will transfer its rights for royalties on sales outside Japan to Royalty Pharma. In turn, Eisai will obtain $110m in upfront payments and is eligible for up to an additional $220m, contingent on marketing approvals for the drug in the US for some indications.

DA: 36 PA: 85 MOZ Rank: 88

EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES …
eisai.com

https://www.eisai.com/news/2019/pdf/enews201981pdf.pdf

WEBAbout Royalty Pharma. Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties, with over $16 billion in. royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners.

DA: 54 PA: 2 MOZ Rank: 90

Royalty Pharma : Announces Agreement to Purchase Future …
marketscreener.com

https://www.marketscreener.com/quote/stock/EPIZYME-INC-13314771/news/Royalty-Pharma-Announces-Agreement-to-Purchase-Future-Royalties-on-Tazemetostat-from-Eisai-for-33-29518299/

WEBNov 5, 2019 · Under the terms of its agreement with Eisai, Royalty Pharma has acquired Eisai's future worldwide royalties on net sales by Epizyme of tazemetostat outside of Japan, for an upfront payment of $110 million plus up to an additional $220 million for the remainder of the royalty upon FDA approval of tazemetostat for certain indications.

DA: 71 PA: 91 MOZ Rank: 51

Royalty Pharma | Funding the next wave of biopharma innovation
royaltypharma.com

https://www.royaltypharma.com/

WEBOur firm. We operate at the intersection of science, medicine and investing. We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences. Learn more. #1. Buyer of biopharma royalties. >$30bn. Announced transactions since founding. >80. Royalty acquisitions since founding.

DA: 60 PA: 77 MOZ Rank: 8

BRIEF—Eisai sells royalty rights for tazemetostat
thepharmaletter.com

https://www.thepharmaletter.com/in-brief/brief-eisai-sells-royalty-rights-for-tazemetostat

WEB05-11-2019 Print. Eisai has sold ex-Japan royalty rights for the investigational anti-cancer agent tazemetostat to Royalty Pharma, for $110 million upfront and up to $220 million based on marketing approvals in the USA. Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme.

DA: 31 PA: 95 MOZ Rank: 41

Eisai transfers rights to Royalty Pharma relating to net sales of …
news-medical.net

https://www.news-medical.net/news/20191105/Eisai-transfers-rights-to-Royalty-Pharma-to-receive-royalties-on-net-sales-of-tazemetostat-drug.aspx

WEBNov 5, 2019 · Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent...

DA: 55 PA: 96 MOZ Rank: 31

EISAI TRANSFERS ALL FUTURE ECONOMIC RIGHTS FOR …
eisai.com

https://www.eisai.com/news/2023/news202348.html

WEBJun 30, 2023 · 1. About Elacestrant. Elacestrant is a selective estrogen receptor degrader discovered by Eisai. Eisai has granted Radius Health, Inc. an exclusive worldwide license for elacestrant. In January 2023, Food and Drug Administration (FDA) approved elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

DA: 87 PA: 47 MOZ Rank: 83